奥沙利铂+替吉奥化疗方案在高龄晚期胃癌患者治疗中的应用

目的:研究奥沙利铂+替吉奥化疗方案在高龄晚期胃癌患者治疗中的应用效果。方法:选择2011年8月至2013年8月在我院接受化疗的高龄晚期胃癌患者68例，分为实验组(34例)与对照组（34例），实验组以奥沙利铂+替吉奥方案化疗，对照组以FOLFOX6方案化疗，观察两组患者近期疗效、临床受益反应、免疫功能及不良反应。结果:经2个周期的化疗，实验组RR（61.76%）高于对照组RR（35.29%），存在显著统计学差异（P＜0.05）；实验组受益率（61.76%）显著高于对照组受益率（35.29%），存在显著统计学差异（P＜0.05）。两组患者化疗后CD3+、CD8+以及CD19+等免疫功能指标与化疗前比较（P＞0.05）；两组患者化疗后CD4+与CD4+/CD8+与化疗前组内比较（P＜0.05）；两组患者化疗后CD4+组间比较（P＜0.05）,均存在显著统计学差异。实验组Ⅰ-Ⅱ度不良反应发生率均低于对照组，两组间除恶心呕吐发生率存在统计学差异（P＜0.05）外，其他不良反应均无统计学差异（P＞0.05）。结论:奥沙利铂+替吉奥化疗方案疗效显著，不良反应发生率低，适合耐受程度较差的高龄晚期胃癌患者的治疗。

Research on application of oxaliplatin + S-1 chemotherapy in the treatment of elderly patients with gastric cancer

Objective:To study the effect of oxaliplatin+S-1 chemotherapy in the treatment of elderly patients with gastric cancer.Methods:Elderly patients with gastric cancer treated with chemotherapy 68 cases were divided into experimental group(34 cases) and control group(34 cases).The experimental group were treated with oxaliplatin+S-1 chemotherapy,the control group with chemotherapy FOLFOX6 scheme.Results:After 2 cycles of chemotherapy,in experiment group RR(61.76%),higher than the controls(35.29%),(P＜0.05).Experimental group benefit benefit rate(61.76%) was significantly higher than control group(35.29%),P＜0.05.Two groups of patients after chemotherapy CD3+,CD8+,CD19+ immune function indexes(P＞0.05).CD4+ and CD4+ /CD8+compared with before chemotherapy(P＜0.05). Ⅰ-Ⅱdegree side effects were lower than the control group(P＜0.05),the other side effects were no statistical difference(P>0.05).Conclusion:Oxaliplatin+S-1 chemotherapy effect is good with low incidence of adverse reaction,suitable for elderly patients with gastric cancer.